Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07671092 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC

StatusRecruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint reworded 2 of 2 changed
See other at-risk trials from RayzeBio, Inc.

Record History

  1. Recruitment opened Trial sites expanded: 1 → 4 locations · Primary completion date: Jul 2027 to Aug 2027 · Completion date: Oct 2027 to Nov 2027 · 3 more Show 6 more changesShow less
    • Trial sites expanded: 1 → 4 locations
    • Primary completion date: Jul 2027 to Aug 2027
    • Completion date: Oct 2027 to Nov 2027
    • Start date changed from estimate of Jun 2026 to Jun 15, 2026
    • Interventions: RYZ211/212 (Diagnostic Test) to RYZ211/212 (Diagnostic Test)
    • Eligibility criteria expanded, about 3 words
  2. Primary endpoint(s) modified Eligibility criteria shortened, about 25 words · Study title shortened, about 4 wordsv2 Show 2 more changesShow less
    • Eligibility criteria shortened, about 25 words
    • Study title shortened, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
RayzeBio, Inc.
8 trials monitored
See 3 trials at risk
Breast Cancer
5,213 trials monitored
See 271 trials at risk
Non-Small Cell Lung Cancer (NSCLC)
2,932 trials monitored
See 157 trials at risk
Bladder Cancer
1,022 trials monitored
See 71 trials at risk
and 1 more disease
This imaging study aims to assess the feasibility, biodistribution, and dosimetry of the imaging agent in subjects with metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC.
Trial Details
NCT Number NCT07671092
Lead Sponsor RayzeBio, Inc.
Conditions Metastatic Urothelial Carcinoma, Breast Cancer, TNBC - Triple-Negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, NSCLC
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov